Page URL: https://www.bionews.org.uk/page_89585

Gene therapy trials under review following third cancer case

7 March 2005
By BioNews
Appeared in BioNews 298

The US Food and Drug Administration (FDA) has recommended that gene therapy treatments for an inherited immune disorder are limited to those who have no alternative. The move follows news that a third child in a similar French trial has developed leukaemia. The trial for X-linked severe combined immunodeficiency disorder (X-SCID), based at the Necker Hospital in Paris, was halted in January. In the UK, the Gene Therapy Advisory Committee (GTAC) is set to carry out a safety review of an X-SCID trial underway at the Institute of Child Health.

Eleven patients affected by X-SCID have been treated in the French trial so far. While most have responded extremely well to the therapy, the trial was suspended in late 2002, after two patients developed symptoms of leukaemia. One of these boys is now in remission, but the other has since died. The AFSSAPS (French Agency for Health Product Safety) gave permission for the trial to restart in May 2004, but suspended the experimental treatment last month, after a third child developed symptoms of leukaemia.

The latest patient to develop side effects received gene therapy treatment at the age of eight months, and was diagnosed with 'lymphoproliferation' - overgrowth of white blood cells - about five weeks ago. Study leader Alain Fischer immediately stopped the study again, and notified the FDA, as well as the AFSSAPS. According to a report in the Washington Post, the FDA does not usually tell the public about clinical trials that it has suspended, but US researchers involved in trials similar to the French one say that the agency has recently told them to suspend their studies. At a meeting held last week, an advisory panel told the FDA that they didn't want to hold up therapy for the small number of children who had failed to respond to bone marrow transplants. It also recommended that gene therapy trials for another type of immune disorder, called ADA-SCID, be allowed to continue.

Fischer says that the recently diagnosed boy is responding well to chemotherapy, and that he is doing well, as are the other trial participants. 'They can cope with infections. That tells us efficacy is there', he said, adding 'there is a future in gene therapy'. Children affected by SCID have a faulty gene that means they have no working immune system, so their bodies cannot fight infections. This life-threatening condition is sometimes called 'bubble boy' disease, as unless they can be successfully treated with a matched bone marrow transplant, patients must spend their lives in a sterile environment.

In the UK, seven children and one adult affected by X-SCID have been successfully treated with gene therapy. A spokesman for the Department of Health said: 'Without treatment, babies with X-SCID rarely survive beyond their first birthday', adding that for children with no matched bone marrow donor, 'gene therapy offers an alternative treatment'. The Committee on Safety of Medicines and GTAC will meet this month to review all X-SCID studies data, the Daily Telegraph reports.

SOURCES & REFERENCES
Boy's Cancer Prompts FDA to Halt Gene Therapy
The Washington Post |  4 March 2005
Check on gene therapy after leukaemia scare in France
The Daily Telegraph |  4 March 2005
Gene Therapy Is Facing a Crucial Hearing
The New York Times |  3 March 2005
U.S. Panel Recommends Limiting Gene Therapy Trials
Yahoo Daily News |  6 March 2005
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
29 April 2019 - by Helen Robertson 
Infants born with a severe immunodeficiency disorder have been successfully treated in a new gene therapy trial...
8 November 2009 - by Dr Rebecca Robey 
Gene therapy has been used to treat two young boys with a devastating and fatal brain disease called adrenoleukodystrophy (ALD). Two years after treatment, both boys showed signs that the disease had stopped progressing and that there were no serious side effects from the gene therapy. These results, published in the journal Science, show huge promise, both for the future treatment of ALD and for the revival of investigations into the use of gene therapy to treat a wide variety ...
2 February 2009 - by Dr Megan Allyse 
Researchers in Italy and Israel have announced that they have successfully used gene therapy to treat ten children who suffer from a rare form of severe combined immunodeficiency (SCID) called ADA-SCID. The trial marks one of the first successful uses of gene therapy since past trials of...
27 April 2006 - by BioNews 
Replacement genes used to treat an inherited immune disorder could trigger cancer, new research carried out on rodents suggests. The study, published in the journal Nature, shows that treating mice with a normal copy of the gene defective in X-linked severe combined immune deficiency (X-SCID) results in cancer of the...
23 January 2006 - by BioNews 
US researchers have discovered how to expand a population of blood stem cells growing in the laboratory, a finding that offers hope for patients requiring bone marrow transplants. It also holds promise for some gene therapy treatments, say the team, who are based at the Whitehead Institute in Cambridge, Massachusetts...
31 January 2005 - by BioNews 
A gene therapy trial for an inherited immune deficiency disorder has been suspended again, following the appearance of complications in a third child. Eleven patients affected by X-linked severe combined immunodeficiency disorder (X-SCID) have so far been treated by the team, based at the Necker Hospital in Paris. While most...
17 December 2004 - by BioNews 
Four children who received gene therapy for a severe inherited immune disorder are now all at home living normal lives, UK scientists report. The boys, who were affected by severe combined immunodeficiency (SCID), received the pioneering treatment at Great Ormond Street Hospital in London. In a commentary accompanying the study...
14 June 2004 - by BioNews 
A French gene therapy trial halted after two participants developed leukaemia looks set to restart after a 22-month suspension, reports Nature. Scientists at the Necker hospital in Paris successfully treated nine children with an inherited immune system disorder called X-linked severe combined immune deficiency (X-SCID). But the trial, along...
17 October 2003 - by BioNews 
US and European scientists have published results confirming that a gene therapy technique triggered leukaemia in two boys taking part in a trial at the Necker hospital, Paris. Their findings, which appear in Science, show that the virus used to deliver the therapeutic gene activated a cancer-causing gene. Eleven boys...
21 July 2003 - by BioNews 
A second patient in a gene therapy trial taking place at Great Ormond Street Hospital in London has been successfully treated, his parents and doctors announced last week. Christopher Reid, now two years old, received gene therapy for the immune system disorder X-linked severe combined immune deficiency (X-SCID) in December...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.